Literature DB >> 26152403

APOL1 nephropathy risk variants are associated with altered high-density lipoprotein profiles in African Americans.

Orlando M Gutiérrez1, Suzanne E Judd2, Marguerite R Irvin3, Degui Zhi2, Nita Limdi4, Nicholette D Palmer5, Stephen S Rich6, Michèle M Sale6, Barry I Freedman7.   

Abstract

BACKGROUND: Two independent coding variants in the apolipoprotein L1 gene (APOL1), G1 and G2, strongly associate with nephropathy in African Americans; associations with cardiovascular disease are more controversial. Although APOL1 binds plasma high-density lipoproteins (HDLs), data on APOL1 risk variant associations with HDL subfractions are sparse.
METHODS: Two APOL1 G1 single nucleotide polymorphisms and the G2 insertion/deletion polymorphism were genotyped in 2010 Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study participants with nuclear magnetic resonance spectroscopy-based lipoprotein subfraction measurements. Linear regression was used to model associations between numbers of APOL1 G1/G2 risk variants and HDL subfractions, adjusting for demographic, clinical and ancestral covariates.
RESULTS: Female sex and higher percentage of African ancestry were positively associated with the number of APOL1 G1/G2 risk alleles. In the unadjusted analysis, mean (standard error) small HDL concentrations (μmol/L) for participants with zero, one and two G1/G2 risk alleles were 19.0 (0.2), 19.7 (0.2) and 19.9 (0.4), respectively (P = 0.02). Adjustment for age, sex, diabetes and African ancestry did not change the results but strengthened the statistical significance (P = 0.004). No significant differences in large or medium HDL, very low-density lipoprotein or low-density lipoprotein particle concentrations were observed by APOL1 genotype.
CONCLUSIONS: Greater numbers of APOL1 G1/G2 risk alleles were associated with higher small HDL particle concentrations in African Americans. These results may suggest novel areas of investigation to uncover reasons for the association between APOL1 risk variants with adverse outcomes in African Americans.
© The Author 2015. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.

Entities:  

Keywords:  APOL1; chronic kidney disease; ethnic disparities; genetics

Mesh:

Substances:

Year:  2015        PMID: 26152403      PMCID: PMC4805128          DOI: 10.1093/ndt/gfv229

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  37 in total

1.  Effects of insulin resistance and type 2 diabetes on lipoprotein subclass particle size and concentration determined by nuclear magnetic resonance.

Authors:  W Timothy Garvey; Soonho Kwon; Deyi Zheng; Sara Shaughnessy; Penny Wallace; Amy Hutto; Kimberly Pugh; Alicia J Jenkins; Richard L Klein; Youlian Liao
Journal:  Diabetes       Date:  2003-02       Impact factor: 9.461

2.  Development of a proton nuclear magnetic resonance spectroscopic method for determining plasma lipoprotein concentrations and subspecies distributions from a single, rapid measurement.

Authors:  J D Otvos; E J Jeyarajah; D W Bennett; R M Krauss
Journal:  Clin Chem       Date:  1992-09       Impact factor: 8.327

3.  Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy.

Authors:  J D Otvos; E J Jeyarajah; D W Bennett
Journal:  Clin Chem       Date:  1991-03       Impact factor: 8.327

4.  Apolipoprotein L, a new human high density lipoprotein apolipoprotein expressed by the pancreas. Identification, cloning, characterization, and plasma distribution of apolipoprotein L.

Authors:  P N Duchateau; C R Pullinger; R E Orellana; S T Kunitake; J Naya-Vigne; P M O'Connor; M J Malloy; J P Kane
Journal:  J Biol Chem       Date:  1997-10-10       Impact factor: 5.157

5.  The reasons for geographic and racial differences in stroke study: objectives and design.

Authors:  Virginia J Howard; Mary Cushman; Leavonne Pulley; Camilo R Gomez; Rodney C Go; Ronald J Prineas; Andra Graham; Claudia S Moy; George Howard
Journal:  Neuroepidemiology       Date:  2005-06-29       Impact factor: 3.282

6.  Altered properties of high density lipoprotein subfractions in obese subjects.

Authors:  T Sasahara; T Yamashita; D Sviridov; N Fidge; P Nestel
Journal:  J Lipid Res       Date:  1997-03       Impact factor: 5.922

7.  Nuclear magnetic resonance lipoprotein abnormalities in prediabetic subjects in the Insulin Resistance Atherosclerosis Study.

Authors:  Andreas Festa; Ken Williams; Anthony J G Hanley; James D Otvos; David C Goff; Lynne E Wagenknecht; Steven M Haffner
Journal:  Circulation       Date:  2005-06-28       Impact factor: 29.690

8.  Lipoproteins in the DCCT/EDIC cohort: associations with diabetic nephropathy.

Authors:  Alicia J Jenkins; Timothy J Lyons; Deyi Zheng; James D Otvos; Daniel T Lackland; Daniel McGee; W Timothy Garvey; Richard L Klein
Journal:  Kidney Int       Date:  2003-09       Impact factor: 10.612

9.  Relation of lipoprotein subclasses as measured by proton nuclear magnetic resonance spectroscopy to coronary artery disease.

Authors:  D S Freedman; J D Otvos; E J Jeyarajah; J J Barboriak; A J Anderson; J A Walker
Journal:  Arterioscler Thromb Vasc Biol       Date:  1998-07       Impact factor: 8.311

10.  Increased burden of cardiovascular disease in carriers of APOL1 genetic variants.

Authors:  Kaoru Ito; Alexander G Bick; Jason Flannick; David J Friedman; Giulio Genovese; Michael G Parfenov; Steven R Depalma; Namrata Gupta; Stacey B Gabriel; Herman A Taylor; Ervin R Fox; Christopher Newton-Cheh; Sekar Kathiresan; Joel N Hirschhorn; David M Altshuler; Martin R Pollak; James G Wilson; J G Seidman; Christine Seidman
Journal:  Circ Res       Date:  2013-12-30       Impact factor: 17.367

View more
  16 in total

1.  How complicated can it be? The link between APOL1 risk variants and lipoprotein heterogeneity in kidney and cardiovascular diseases.

Authors:  Chien-An A Hu; Patricio E Ray
Journal:  Nephrol Dial Transplant       Date:  2015-10-03       Impact factor: 5.992

Review 2.  The Impact of APOL1 on Chronic Kidney Disease and Hypertension.

Authors:  Todd W Robinson; Barry I Freedman
Journal:  Adv Chronic Kidney Dis       Date:  2019-03       Impact factor: 3.620

3.  Kidney function is associated with an altered protein composition of high-density lipoprotein.

Authors:  Katya B Rubinow; Clark M Henderson; Cassianne Robinson-Cohen; Jonathan Himmelfarb; Ian H de Boer; Tomas Vaisar; Bryan Kestenbaum; Andrew N Hoofnagle
Journal:  Kidney Int       Date:  2017-07-26       Impact factor: 10.612

Review 4.  The Apolipoprotein L1 Gene and Cardiovascular Disease.

Authors:  Todd W Robinson; Barry I Freedman
Journal:  Methodist Debakey Cardiovasc J       Date:  2016 Oct-Dec

Review 5.  Ten years in: APOL1 reaches beyond the kidney.

Authors:  Joshua S Waitzman; Jennie Lin
Journal:  Curr Opin Nephrol Hypertens       Date:  2019-07       Impact factor: 2.894

6.  Association of APOL1 Risk Alleles With Cardiovascular Disease in Blacks in the Million Veteran Program.

Authors:  Alexander G Bick; Elvis Akwo; Cassianne Robinson-Cohen; Kyung Lee; Julie Lynch; Themistocles L Assimes; Scott DuVall; Todd Edwards; Huaying Fang; S Matthew Freiberg; Ayush Giri; Jennifer E Huffman; Jie Huang; Leland Hull; Rachel L Kember; Derek Klarin; Jennifer S Lee; Michael Levin; Donald R Miller; Pradeep Natarajan; Danish Saleheen; Qing Shao; Yan V Sun; Hua Tang; Otis Wilson; Kyong-Mi Chang; Kelly Cho; John Concato; J Michael Gaziano; Sekar Kathiresan; Christopher J O'Donnell; Daniel J Rader; Philip S Tsao; Peter W Wilson; Adriana M Hung; Scott M Damrauer
Journal:  Circulation       Date:  2019-07-24       Impact factor: 29.690

7.  Characterization of circulating APOL1 protein complexes in African Americans.

Authors:  Allison Weckerle; James A Snipes; Dongmei Cheng; Abraham K Gebre; Julie A Reisz; Mariana Murea; Gregory S Shelness; Gregory A Hawkins; Cristina M Furdui; Barry I Freedman; John S Parks; Lijun Ma
Journal:  J Lipid Res       Date:  2015-11-18       Impact factor: 5.922

8.  APOL1 Nephropathy Risk Alleles and Mortality in African American Adults: A Cohort Study.

Authors:  Orlando M Gutiérrez; Marguerite R Irvin; Neil A Zakai; Rakhi P Naik; Ninad S Chaudhary; Michelle M Estrella; Sophie Limou; Suzanne E Judd; Mary Cushman; Jeffrey B Kopp; Cheryl A Winkler
Journal:  Am J Kidney Dis       Date:  2019-09-26       Impact factor: 8.860

9.  APOL1 Nephropathy Risk Variants and Incident Cardiovascular Disease Events in Community-Dwelling Black Adults.

Authors:  Orlando M Gutiérrez; Marguerite R Irvin; Ninad S Chaudhary; Mary Cushman; Neil A Zakai; Victor A David; Sophie Limou; Nathalie Pamir; Alex P Reiner; Rakhi P Naik; Michele M Sale; Monika M Safford; Hyacinth I Hyacinth; Suzanne E Judd; Jeffrey B Kopp; Cheryl A Winkler
Journal:  Circ Genom Precis Med       Date:  2018-06

10.  Race, APOL1 Risk Variants, and Clinical Outcomes among Older Adults: The ARIC Study.

Authors:  Teresa K Chen; Josef Coresh; Natalie Daya; Shoshana H Ballew; Adrienne Tin; Deidra C Crews; Morgan E Grams
Journal:  J Am Geriatr Soc       Date:  2020-09-07       Impact factor: 5.562

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.